26 · 03 · 19 - Our clients - ABG-IP
Omomyc, the Myc inhibitor developed by Peptomyc, is closer to the clinic
19 · 09 · 18 - Our clients - ABG IP
Spherium Biomed announces positive outcome of Cyclatop’s (SP14019) clinical trial showing that the product is safe and efficacious for the treatment of Atopic Dermatitis in adults and infants
28 · 06 · 18 - Our clients - ABG IP
Peptomyc S.L. wins the Best Business Initiative Award at the 25th Young Entrepreneur Awards
22 · 05 · 18 - Our clients - ABG IP
Spherium Biomed announces positive outcome of a phase I/IIa clinical trial for Mucomel®
24 · 04 · 18 - Our clients - ABG IP
Spherium Biomed completed enrolment in the Cyclatop© (SP14019) trial in February 2018
19 · 04 · 18 - Our clients - ABG IP
Spherium Biomed has signed a licensing agreement with Simini Technologies from Canada
15 · 03 · 18 - Our clients - ABG IP
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria